New research shows patients lose trust and confidence in doctors that take money for travel, but like it when their doctors are paid as consultants during the development of new products.
Major drugmakers—including Indianapolis-based Eli Lilly and Co.—the British government and a top Alzheimer's research charity are pooling more than $100 million to create a global fund to accelerate efforts to find a treatment or cure.
21-year-old Ryan Reed stunned racing gurus on Feb. 21 by winning his first NASCAR race on stock-car racing’s most hallowed grounds. He did it with a wireless device attached to his stomach feeding a constant stream of data to a dashboard-mounted glucose monitor.
Makers of testosterone drugs must change the products’ labels to clarify that they are approved for only certain disorders, not to help men deal with aging, U.S. regulators said.
Top-down culture change only works in North Korea, says the head of a group of local CEOs that is working broadly and subtly, not tyrannically, to improve Indy’s culture of eating and exercising.
Paris-based drugmaker Sanofi had revenue of $8.4 billion from Lantus last year. It lost U.S. patent protection this month and will lose exclusive rights in Europe in May.
Although the experimental diabetes drug is in final-stage testing and showing promising results, Lilly wants to better understand its effect on liver fat.
The U.S. Department of Justice told Lilly last month its investigation was over—more than a year after the drugmaker paid $29 million to the SEC to settle related bribery allegations.
Takeda Pharmaceutical Co. was ordered by a jury Thursday to pay more than $2.3 million in damages to a former teacher who blamed the company’s Actos diabetes drug for causing his bladder cancer.
After weathering a barrage of patent expirations, the pharmaceutical giant has restocked its pipeline and is positioned to grow.
A Cuban immigrant was sentenced Wednesday to more than six years in prison for his role in the 2010 heist of a Connecticut warehouse in which the robbers filled a tractor-trailer with more than $50 million worth of Eli Lilly and Co. pharmaceuticals.
Eli Lilly and Co. predicted its 2015 sales will come in roughly $1 billion less than analysts have expected, due to the strength of the U.S. dollar against foreign currencies.
Novartis AG is racing to establish itself in the market for new treatments for psoriasis ahead of competing drugs by Amgen Inc. and Eli Lilly and Co. in the United States.
The CEOs of Anthem, Lilly, Zimmer and Hill-Rom tried to woo investors at the J.P. Morgan Healthcare conference by stressing how they’re broadening business beyond plain-old insurance, pharmaceuticals, implants and hospital beds.
Health-coverage managers are becoming more aggressive in demanding discounts and exclusive deals from drugmakers to drive down the cost of medicine, Eli Lilly and Co.’s diabetes business chief says.
A batch of Cialis pills, purportedly made at a plant in Australia, was banned by the FDA from entering the U.S. after the pills were found to contain the active ingredient for rival drug Viagra. Cialis manufacturer Eli Lilly said it doesn’t make any drugs in Australia.
Since Obamcare was expected to boost insurance coverage nationally by 32 million people, drugmakers like Eli Lilly and Co. stood to benefit. But it’s not working out that way. At least not for Lilly.
The Indianapolis-based drugmaker said its long-term strategy is on track, but predicted sales this year would be $20.3 billion to $20.8 billion, a shade below what Wall Street was expecting.
Eli Lilly and Co. wants to combine Novartis with its own animal health business, Elanco, to create the second-largest animal health company in the U.S.
Eli Lilly and Co. could pay more than $570 million to French pharmaceutical company Adocia under an agreement to develop a fast-acting insulin that is in the early stages of clinical testing.
